, 40 patients from whom LRVRE organisms were recovered in clinical specimens were characterized. Epidemiologic investigation and pulsed-field gel electrophoresis patterns indicated a clonal outbreak related to nosocomial spread.
Linezolid, the first drug in the oxazolidinone class, was approved for use in the United States in March 2000 for the treatment of infections due to gram-positive cocci, including vancomycin-resistant enterococci. Despite widespread usage over the past 6 years, surveillance studies have reported rates of linezolid resistance in enterococci of Ͻ0.5% (5) . In May 2004, our 900-bed tertiary care academic medical center encountered its first case of linezolid-resistant, vancomycin-resistant Enterococcus faecium (LRVRE) disease after progressive increases in the utilization of linezolid over the preceding several months. Subsequently, during 2005, 60 unique isolates accounting for 21% of all E. faecium isolates recovered from inpatients were intermediately or fully resistant to linezolid. A retrospective investigation was initiated to determine the nature of this outbreak. The study was performed with the approval of the Institutional Review Board.
We examined the medical records of 40 patients from whom LRVRE were isolated from clinical specimens between October 2004 and July 2005 to ascertain factors that may have contributed to acquisition of the organism and the persistence of the outbreak. Demographic data, clinical characteristics, underlying illnesses, prior exposures to antibiotics, corticosteroids, chemotherapy, hyperalimentation, the presence of an indwelling central venous catheter, hospital location, and survival were recorded. Clinical infectious disease versus colonization was defined by the team attending to each case.
Bacteria were identified, and MICs were initially determined using the MicroScan WalkAway (Dade Behring, West Sacramento, CA). Nonsusceptibility to linezolid (MICs of Ն4 g/ml) was verified by the agar gradient diffusion (Etest) technique (AB Biodisk, Solna, Sweden). LRVRE isolates from 21 of the 40 patients had been stored frozen at Ϫ70°C and were tested by pulsed-field gel electrophoresis (PFGE) to determine genetic relatedness. PFGE was performed using techniques described previously with a few minor modifications (6) . Banding patterns were analyzed using GelCompar II (Applied Maths, Austin, TX) and interpreted as described by Tenover et al. (11) . We performed PFGE on 12 contemporary vancomycinresistant enterococcus isolates from our institution that were susceptible to linezolid (LSVRE) for comparison. The data management and statistical analysis were performed using Epi Info 3.3.
Etest MICs confirmed linezolid resistance initially identified by the MicroScan for all E. faecium isolates, with values ranging from 8 to Ͼ256 g/ml (MIC 50 ϭ 32 g/ml, MIC 90 ϭ 256 g/ml). All LRVRE isolates were susceptible to tetracycline (MICs of Յ4 g/ml), and all but one were resistant to ciprofloxacin (MICs of Ն4 g/ml).
Among the 40 patients whose records were examined, the median age was 54 years (range, 21 to 93 years). Twenty-two (55%) patients had evidence of disease due to LRVRE. The bloodstream (eight patients) and urinary tract (nine patients) were the most common sites of specimen origin. Nine patients overall and six with LRVRE clinical infection died during hospitalization. Serious comorbidities were encountered frequently, with diabetes mellitus and end-stage renal disease being the most common (Table 1 ). All patients received antibiotics prior to the isolation of LRVRE. Fluoroquinolones and vancomycin were the most common agents administered. Only six (15%) patients received linezolid prior to contracting LRVRE (Table 2) .
LRVRE occurred hospital-wide in several different types of units. Twenty-eight (70%) patients had spent time in one or more of nine intensive care units (ICUs). Seventeen (42.5%) were in a specific medical/coronary care ICU prior to acquiring LRVRE. During the first 4 months of the outbreak, 11 of 14 (78.6%) patients spent time in this particular ICU prior to acquiring LRVRE. Many patients were transferred among (Fig. 1) . The remaining two isolates were unique from the dominant clone and from each other. All LRVRE isolates were distinct as determined by PFGE from a sample of 12 contemporary LSVRE strains isolated from patients housed in these same hospital locations and from 185 LSVRE strains isolated earlier at our institution (data not shown), indicating that a newly introduced clone was responsible for most of the LRVRE infections we encountered in 2004 and early 2005.
The clinical management of enterococcal infections has been greatly compromised by the emergence of vancomycinresistant strains over the past two decades (4). Linezolid is one of several new compounds useful for treating these resistant organisms. The identification of linezolid resistance among enterococci further complicates the management of these infections and greatly limits the available treatment options. Risk factors that we identified in patients with LRVRE were typical of what we have observed with LSVRE.
Linezolid resistance in enterococci was recognized soon after its clinical debut, although previously published reports have involved a single patient or a very limited number of cases (1-3, 7, 8, 10 ). Most linezolid-resistant isolates examined thus far have had the same 23S rRNA mutation in domain V, G2576U (9) . A gene-dose effect has been observed that correlates the magnitude of the MIC with the number of loci containing this mutation (9) . The wide range of linezolid MICs we encountered also supports this concept.
The rate of development of LRVRE is unknown, but de novo resistance has been documented in several instances when PFGE comparisons were made between susceptible and resistant isolates in the same patient after exposure to linezolid (1, 2, 8) . However, as we have demonstrated, prior exposure to Identification of two other unrelated clones of LRVRE from different patients indicates that the development and spread of resistance was not an isolated event. Our experience suggests that use and exposure to agents other than linezolid, fluoroquinolones in particular, may be important to the emergence of linezolid resistance. Prudent antibiotic utilization practices must also be incorporated into an institutional strategy to limit the burden of resistant pathogens. We are now discouraging the use of fluoroquinolones in the hospital in general and have recommended that alternatives such as daptomycin be used in lieu of linezolid for treating infections due to vancomycinresistant enterococci.
